Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: An anti-interleukin-6 receptor antibody

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Yanagida, Mitsuaki ^a   Kawasaki, Mikiko ^a   Fujishiro, Maki ^a   Miura, Masako ^a   Ikeda, Keigo ^b   Nozawa, Kazuhisa ^c   Kaneko, Hiroshi ^d   Morimoto, Shinji ^b   Takasaki, Yoshinari ^c   Ogawa, Hideoki ^a   Takamori, Kenji ^a   Sekigawa, Iwao ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d National Center for Global Health and Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISOLONE; PROTEOME; TOCILIZUMAB; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEOMICS; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; TANDEM MASS SPECTROMETRY; BLOOD; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; SERUM; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PROTEOME; RECEPTORS, INTERLEUKIN-6; SERUM;

EID: 84884251098     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/607137     Document Type: Article

References (41)

1. Maini R. N., Elliott M. J., Brennan F. M., Williams R. O., Chu C. Q., Paleolog E., Charles P. J., Taylor P. C., Feldmann M., Monoclonal anti-TNF α antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunological Reviews 1995 144 195 223 2-s2.0-0028990467
2. Kempeni J., Preliminary results of early clinical trials with the fully human anti-TNF α monoclonal antibody D2E7. Annals of the Rheumatic Diseases 1999 58 supplement 1 I70 I72 2-s2.0-0032705008 10.1136/ard.58.2008.i70
3. Mohler K. M., Torrance D. S., Smith C. A., Goodwin R. G., Stremler K. E., Fung V. P., Madani H., Widmer M. B., Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. The Journal of Immunology 1993 151 3 1548 1561 2-s2.0-0027198002
4. Mihara M., Nishimoto N., Ohsugi Y., The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opinion on Biological Therapy 2005 5 5 683 690 2-s2.0-20344381320 10.1517/14712598.5.5.683
5. Dall'Era M., Davis J., CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004 13 5 372 376 2-s2.0-2942733370 10.1191/0961203303lu1029oa
6. Sekigawa I., Yanagida M., Iwabuchi K., Kaneda K., Kaneko H., Takasaki Y., Jung G., Sone S., Tanaka Y., Ogawa H., Takamori K., Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis faetor- α antibody therapy. Clinical and Experimental Rheumatology 2008 26 2 261 267 2-s2.0-43349093924
7. Yanagida M., Jung G., Tanaka Y., Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor. International Journal of Rheumatic Diseases 2012 15 5 486 495 10.1111/j.1756-185X.2012.01816.x
8. Nozawa K., Fujishiro M., Kawasaki M., Kaneko H., Iwabuchi K., Yanagida M., Suzuki F., Miyazawa K., Takasaki Y., Ogawa H., Takamori K., Sekigawa I., Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Research & Therapy 2009 11 6, article R174 2-s2.0-77952476189 10.1186/ar2863
9. Fujishiro M., Nozawa K., Kawasaki M., Yamaguchi A., Iwabuchi K., Yanagida M., Suzuki F., Miyazawa K., Fukui H., Kaneko K., Ogawa H., Takamori K., Takasaki Y., Sekigawa I., Regenerating gene (REG) 1 alpha promotes pannus progression in patients with rheumatoid arthritis. Modern Rheumatology 2012 22 2 228 237 2-s2.0-84255198391 10.1007/s10165-011-0564-y
10. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A. Jr., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 1988 31 3 315 324 2-s2.0-0023945481
11. Steinbrocker O., Traeger C. H., Batterman R. C., Therapeutic criteria in rheumatoid arthritis. Journal of the American Medical Association 1949 140 8 659 662 2-s2.0-72649098710
12. Prevoo M. L. L., van'T Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B., van Riel P. L., Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism 1995 38 1 44 48 2-s2.0-0028815803 10.1002/art.1780380107
13. Tirumalai R. S., Chan K. C., Prieto D. A., Issaq H. J., Conrads T. P., Veenstra T. D., Characterization of the low molecular weight human serum proteome. Molecular & Cellular Proteomics 2003 2 10 1096 1103 2-s2.0-0346364695
14. Anderson N. L., Anderson N. G., The human plasma proteome: history, character, and diagnostic prospects. Molecular & Cellular Proteomics 2002 1 11 845 867 2-s2.0-0001644020
15. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H., Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences of the United States of America 1987 84 20 7251 7255 2-s2.0-0023432812
16. Cylwik B., Chrostek L., Gindzienska-Sieskiewicz E., Sierakowski S., Szmitkowski M., Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. Advances in Medical Sciences 2010 55 1 80 85 2-s2.0-77954518587 10.2478/v10039-010-0006-7
17. Petersen C. M., Alpha 2-macroglobulin and pregnancy zone protein. Serum levels, alpha 2-macroglobulin receptors, cellular synthesis and aspects of function in relation to immunology. Danish Medical Bulletin 1993 40 4 409 446 2-s2.0-0027668775
18. Horne C. H. W., Thomson A. W., Hunter C. B., Tunstall A. M., Towler C. M., Billingham M. E., Pregnancy-associated α 2-glycoprotein (α 2-PAG) and various acute phase reactants in rheumatoid arthritis and osteoarthritis. Biomedicine 1979 30 2 90 94 2-s2.0-0018761687
19. Serada S., Fujimoto M., Ogata A., Terabe F., Hirano T., Iijima H., Shinzaki S., Nishikawa T., Ohkawara T., Iwahori K., Ohguro N., Kishimoto T., Naka T., iTRAQ-based proteomic identification of leucine-rich α -2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Annals of the Rheumatic Diseases 2010 69 4 770 774 2-s2.0-77950308484 10.1136/ard.2009.118919
20. Ajeganova S., Fiskesund R., de Faire U., Hafström I., Frostegård J., Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis-a one-year study. Clinical and Experimental Rheumatology 2011 29 6 942 950 2-s2.0-84857573905
21. Kawashiri S. Y., Kawakami A., Yamasaki S., Imazato T., Iwamoto N., Fujikawa K., Aramaki T., Tamai M., Nakamura H., Ida H., Origuchi T., Ueki Y., Eguchi K., Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatology International 2011 31 4 451 456 2-s2.0-79954438244 10.1007/s00296-009-1303-y
22. Soubrier M., Jouanel P., Mathieu S., Poujol D., Claus D., Dubost J. J., Ristori J. M., Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008 75 1 22 24 2-s2.0-37649012449 10.1016/j.jbspin.2007.04.014
23. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., Nakano N., Ikeda Y., Sasaki T., Nishioka K., Hara M., Taguchi H., Kimura Y., Kato Y., Asaoku H., Kumagai S., Kodama F., Nakahara H., Hagihara K., Yoshizaki K., Kishimoto T., Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005 106 8 2627 2632 2-s2.0-27144488346 10.1182/blood-2004-12-4602
24. Honkanen V., Konttinen Y. T., Mussalo-Rauhamaa H., Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clinical and Experimental Rheumatology 1989 7 5 465 469 2-s2.0-0024841050
25. Takeuchi T., Kotani T., Nakanishi T., Tabushi-Matsumura Y., Takubo T., Makino S., Proteomic analysis of changes in the serum protein profile by anti-TNF-alpha therapy. Rinsho Byori 2010 58 4 332 336 2-s2.0-77955855332
26. Ateş A., Kinikli G., Turgay M., Duman M., Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis. Scandinavian Journal of Immunology 2004 59 3 315 320 2-s2.0-1842557380 10.1111/j.0300-9475.2004.01389.x
27. Ugur M., Yildirim K., Kiziltunc A., Erdal A., Karatay S., Senel K., Correlation between soluble intercellular adhesion molecule 1 level and extracellular superoxide dismutase activity in rheumatoid arthritis: a possible association with disease activity. Scandinavian Journal of Rheumatology 2004 33 4 239 243 2-s2.0-4444270259 10.1080/03009740310004054
28. Banerji S., Ni J., Wang S.-X., Clasper S., Su J., Tammi R., Jones M., Jackson D. G., LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. The Journal of Cell Biology 1999 144 4 789 801 2-s2.0-0033593793 10.1083/jcb.144.4.789
29. Xu H., Edwards J., Banerji S., Prevo R., Jackson D. G., Athanasou N. A., Distribution of lymphatic vessels in normal and arthritic human synovial tissues. Annals of the Rheumatic Diseases 2003 62 12 1227 1229 2-s2.0-0344197018 10.1136/ard.2003.005876
30. Lehmann J. M., Holzmann B., Breitbart E. W., Schmiegelow P., Riethmuller G., Johnson J. P., Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Research 1987 47 3 841 845 2-s2.0-0023132289
31. Lehmann J. M., Riethmuller G., Johnson J. P., MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proceedings of the National Academy of Sciences of the United States of America 1989 86 24 9891 9895 2-s2.0-0024791128 10.1073/pnas.86.24.9891
32. Neidhart M., Wehrli R., Bruhlmann P., Michel B. A., Gay R. E., Gay S., Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis. Arthritis & Rheumatism 1999 42 4 622 630
33. Siiteri P. K., Murai J. T., Hammond G. L., Nisker J. A., Raymoure W. J., Kuhn R. W., The serum transport of steroid hormones. Recent Progress in Hormone Research 1982 38 457 510 2-s2.0-0020022809
34. Mirone L., Altomonte L., D'Agostino P., Zoli A., Barini A., Magaró M., A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity. Clinical Rheumatology 1996 15 1 15 19 2-s2.0-0030048625 10.1007/BF02231678
35. Simó R., Barbosa-Desongles A., Sáez-Lopez C., Lecube A., Hernandez C., Selva D. M., Molecular mechanism of TNF α -induced down-regulation of SHBG expression. Molecular Endocrinology 2012 26 3 438 446 2-s2.0-84857530047 10.1210/me.2011-1321
36. Haendler B., Kratzschmar J., Theuring F., Schleuning W. D., Transcripts for cysteine-rich secretory protein-1 (CRISP-1; DE/AEG) and the novel related CRISP-3 are expressed under androgen control in the mouse salivary gland. Endocrinology 1993 133 1 192 198 2-s2.0-0027321118 10.1210/en.133.1.192
37. Ribeiro F. R., Paulo P., Costa V. L., Barros-Silva J. D., Ramalho-Carvalho J., Jerónimo C., Henrique R., Lind G. E., Skotheim R. I., Lothe R. A., Teixeira M. R., Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS ONE 2011 6 7 2-s2.0-79960632568 10.1371/journal.pone.0022317 e22317
38. Straub R. H., Härle P., Atzeni F., Weidler C., Cutolo M., Sarzi-Puttini P., Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. The Journal of Rheumatology 2005 32 7 1253 1258 2-s2.0-22244432463
39. De Franceschi L., Bosello S., Scambi C., Biasi D., de Santis M., Caramaschi P., Peluso G., La Verde V., Bambara L. M., Ferraccioli G., Proteome analysis of biological fluids from autoimmune-rheumatological disorders. Proteomics Clinical Applications 2011 5 1-2 78 89 2-s2.0-79251592854 10.1002/prca.201000069
40. Hueber W., Tomooka B. H., Batliwalla F., Li W., Monach P. A., Tibshirani R. J., van Vollenhoven R. F., Lampa J., Saito K., Tanaka Y., Genovese M. C., Klareskog L., Gregersen P. K., Robinson W. H., Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Research & Therapy 2009 11 3, article R76 2-s2.0-67649392488 10.1186/ar2706
41. Nozawa K., Fujishiro M., Kawasaki M., Inhibition of connective tissue growth factor ameliorates rheumatoid arthritis in a murine model. Arthritis & Rheumatism 2013 65 6 1477 1486 10.1002/art.37902